Adjuvant Osimertinib In Patients With Resected EGFR-Mutated Stage IB-IIIA Non-Small Cell Lung Cancer: Final Overall Survival Analysis

Lisa Kottschade, APRN, MSN, CNP, FAPO, of the Mayo Clinic, discusses the planned final overall survival analysis from the ADAURA trial. This study randomized eligible patients (stage IB, II, or IIIA NSCLC) to osimertinib 80 mg once daily or placebo until disease recurrence, treatment completion, or a discontinuation criterion was met. ADAURA is the first global phase III study to demonstrate a statistically significant DFS and OS benefit with targeted treatment for patients with EGFRm stage IB to IIIA NSCLC (Abstract LBA3).